About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: ARRY
- CUSIP: 04269X10
- Previous Close: $10.36
- 50 Day Moving Average: $10.84
- 200 Day Moving Average: $7.26
- 52-Week Range: $2.50 - $13.40
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -14.19
- P/E Growth: -1.49
- Market Cap: $1.75B
- Outstanding Shares: 169,007,000
- Beta: 2.12
- Net Margins: -58.57%
- Return on Assets: -49.54%
Companies Related to Array BioPharma:
- Debt-to-Equity Ratio: 2.26%
- Current Ratio: 4.10%
- Quick Ratio: 4.10%
What is Array BioPharma's stock symbol?
Array BioPharma trades on the NASDAQ under the ticker symbol "ARRY."
Where is Array BioPharma's stock going? Where will Array BioPharma's stock price be in 2017?
8 brokerages have issued 1-year target prices for Array BioPharma's shares. Their predictions range from $7.00 to $15.00. On average, they expect Array BioPharma's stock price to reach $11.50 in the next year.
When will Array BioPharma announce their earnings?
Array BioPharma is scheduled to release their next quarterly earnings announcement on Monday, May, 1st 2017.
What are analysts saying about Array BioPharma stock?
Here are some recent quotes from research analysts about Array BioPharma stock:
According to Zacks Investment Research, "Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. " (1/31/2017)
Leerink Swann analysts commented, "We’re at 95% probability-of-success; the current stock valuation prices in less. We believe melanoma represents a small and competitive market, but better tolerability and potential combinability vs. other TKIs could drive differentiation. ARRY also plans to broaden development of encorafenib/ binimetinib in BRAF+ colorectal cancer, which is compelling longer term. Selumetinib Ph III results in KRAS+ Non Small Cell Lung Cancer (NSCLC) are expected in 2H. Updating estimates to reflect F3Q16 results. Maintaining OP rating and $6 PT. Binimetinib regulatory filing in NRAS+ melanoma still expected in 1H16; NEMO full data at ASCO, June 6th. We currently forecast 2025E US sales of $24M with peak penetration of 50% in NRAS+ 2nd/3rd-line melanoma following immune-oncology (IO) therapies, which currently dominate the 1st and 2nd lines of therapy in these pts. Given the poor prognosis of NRAS+ pts, some 2L use is likely. ARRY previously reported a median progression-free survival (PFS) of 2.8 months and plans to report full Ph III data including ORR (Objective Response Rate) and subgroup analysis (PFS & ORR) in IO-treated patients at ASCO. COLUMBUS trial (BRAF+ melanoma) top-line data exp. in 3Q16 (vs. 1H16 prev.) as additional events are needed to trigger the final analysis (which is not uncommon, in our view). We currently assume a 95% probability-of-success (POS) with 20% peak market share (conservative) among MEK/BRAF-treated pts. A potl." (5/5/2016)
Who owns Array BioPharma stock?
Array BioPharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.71%), Orbimed Advisors LLC (9.52%), State Street Corp (3.81%), Franklin Resources Inc. (3.30%), Pinnacle Associates Ltd. (1.90%) and Bogle Investment Management L P DE (1.23%). Company insiders that own Array BioPharma stock include Andrews R Robbins, Kyle Lefkoff, Redmile Group, Llc and Ron Squarer.
Who sold Array BioPharma stock? Who is selling Array BioPharma stock?
Array BioPharma's stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Pinnacle Associates Ltd. and Kopp Investment Advisors LLC.
Who bought Array BioPharma stock? Who is buying Array BioPharma stock?
Array BioPharma's stock was acquired by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, State Street Corp, Franklin Resources Inc., Bogle Investment Management L P DE, FMR LLC, Guggenheim Capital LLC, AQR Capital Management LLC and Putnam Investments LLC.
How do I buy Array BioPharma stock?
Shares of Array BioPharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Array BioPharma stock cost?
One share of Array BioPharma stock can currently be purchased for approximately $10.36.